Researchers found a 15% reduction in colorectal cancer diagnosis among patients with osteoarthritis who took NSAIDs, consistent with previous findings on pre-cancerous polyps. The study supports the need for further research to identify safe NSAID agents for regular preventive therapy.
Researchers found that patients treated with single-drug therapy had shorter overall survival, but those receiving sequential treatment had similar survival rates to combination therapy regimens. The study results challenge conventional clinical practice and suggest a more gentle approach for some patients.
Researchers found a significant link between genetic variation on chromosome 8 and the risk of colorectal cancer, with individuals carrying the specific marker being 23% more likely to develop the disease. The study suggests that this single genetic variation might account for 14% of colorectal cancer cases in Israel.
Researchers at the University of Southern California have identified a common genetic risk factor for colorectal and prostate cancer. The study found that one variant previously associated with prostate cancer also increases the risk of developing colorectal cancer.
Researchers have found a new virus, NV1020, to be effective against colorectal cancer with minimal side effects. The treatment has shown promising results in reducing tumor masses and improving patient survival.
Researchers at Stanford University School of Medicine have identified cancer stem cells in colorectal tumors, which can propagate and maintain the growth of the tumor. These stem cells have been found to be responsible for the spread of cancer to distant sites and are likely to be responsible when tumors resurface or spread.
A large multicenter study examined circulating tumor cells in patients with metastatic colorectal cancer, showing their predictive value for survival and cancer progression. Patients with fewer than 3 CTCs had superior median survival times compared to those with detectable CTCs.
Researchers have found a significant reduction in the overall colorectal tumor miss rate using advanced colonoscopy technologies, establishing a new benchmark for accurate screening and detection. High levels of C-reactive protein are also associated with increased risk of colorectal adenoma in men, but not in women.
A study from Massachusetts General Hospital reveals that aspirin's colorectal cancer prevention mechanism depends on the inhibition of COX-2 enzyme. Regular aspirin intake only reduced the incidence of colorectal tumors that overexpress COX-2, highlighting a potential target for personalized treatment strategies.
Researchers found that pre-operative CT scans in patients experiencing acute appendicitis symptoms may delay surgery, increasing the risk of appendix rupture. Colonoscopies are recommended over flexible sigmoidoscopy for detecting advanced neoplastic lesions, with notable racial disparities observed.
A study published at Digestive Disease Week found that a lifelong vegetarian diet can reduce the risk of colorectal cancer. Additionally, consuming a fatty soup as an appetizer before dinner may lead to reduced food intake in both lean and obese individuals.
A study published in The Lancet found that long-term aspirin use can reduce the risk of colorectal cancer by 37% overall and 74% after 10-15 years. The benefits are likely to outweigh the risks in individuals at increased risk of colon cancer.
A meta-analysis of studies found that controlling for socioeconomic factors reduced racial disparities in colorectal cancer survival. Lower socioeconomic status is linked to poorer health outcomes and reduced access to healthcare.
A new study finds that virtual colonoscopy with removal of lesions 6 mm or greater is the most cost-effective colon cancer screening test. The study reveals that targeting smaller lesions has little impact on reducing CRC incidence and increases financial costs, while also leading to adverse events.
A daily dose of adult-strength aspirin was associated with a moderate decreased cancer risk, particularly for colorectal, prostate, and breast cancers. However, the effect on other types of cancer was not significant.
Researchers found that cetuximab improved overall survival by 23% and reduced disease progression risk by 32%. The drug targets the EGFR receptor on cancer cells, preventing cell growth and triggering an immune response.
Researchers discovered a gene called Atp5a1 that, when mutated, reduces the incidence of polyps in mice. The mutation leads to decreased levels of Atp5a1 gene expression, which may provide insights into its potential role in human cancer.
A large study found that doubling fat intake is linked to a 15% increase in breast cancer risk, regardless of the type of fat consumed. In contrast, higher consumption of lignans, found in plants and whole grains, may be associated with a reduced risk of postmenopausal breast cancer.
Researchers found simultaneous surgeries on colon and liver may reduce length of hospital stay and surgical complications without compromising long-term survival. In certain patient groups, simultaneous surgery was as safe as separate surgeries, potentially leading to better outcomes.
A new study found that routine colonoscopic surveillance improves survival for colorectal cancer patients. Patients who underwent regular follow-up colonoscopies had better five-year survival rates compared to those who did not receive screenings.
A new immunochemical fecal occult blood test (I-FOBT) shows promise in increasing colon cancer screening rates by being more accurate and convenient than traditional methods. The test uses antibodies to detect human blood in stool, eliminating dietary restrictions and allowing for personalized positivity thresholds.
The American College of Physicians recommends periodic health evaluations to improve patient outcomes and reduce healthcare costs. A new study found that immunochemical FOBT is an effective tool for detecting colorectal cancer, with high sensitivity and specificity rates.
A study found significant disparities in colon cancer screening practices by ethnicity, sex, age, education and income level among Medicare patients. Approximately 18.3% of the sample population had been screened for colon cancer during the study period.
A new study found that hairy cell leukemia survivors have an increased risk of developing certain cancers, including Hodgkin lymphoma and thyroid cancer. Meanwhile, a new test may be able to identify patients with a specific type of gene mutation that indicates an inherited form of colorectal cancer or potential response to certain drugs.
New studies using meta-analysis found a significant link between high vitamin D levels and reduced risk of breast and colorectal cancers. Individuals with the highest blood levels of 25-hydroxyvitamin D had the lowest risk of these cancers, with potential protective effects achievable through diet, supplements, or sunlight exposure.
A new report by the European Society for Medical Oncology warns that Europe's aging population is driving a major increase in cancer cases and deaths. The report estimates that there were 3.2 million new cancer cases diagnosed in 2006, with lung cancer remaining the leading cause of death.
Researchers have discovered a new way to fight colorectal cancer by targeting the 'skeletons' of cancer cells, which enable them to reproduce and spread. High-dose PPARgamma inhibitors destroy cancer cell microtubules, reducing their ability to grow and metastasize.
Recent research suggests that regular statin use is not linked to lower colorectal cancer risk, while folate intake does not appear to impact breast cancer risk. However, monitoring of thyroid function may be necessary for patients taking the medication sunitinib, which can cause fatigue and hypothyroidism.
A new study reveals that health-care delivery, particularly screening tests and surgical treatment, contribute to poorer outcomes for African-American patients with colorectal cancer. The study found that African-Americans were more likely to have advanced disease and received less surgical treatment compared to other ethnicities.
Since expanding screening coverage in 1998, the proportion of patients with colon cancer diagnosed at an early stage has increased. The study found that patients diagnosed during periods with universal coverage were significantly more likely to have early-stage illness than those diagnosed in earlier periods.
A study published in Clinical Gastroenterology and Hepatology found that stool DNA testing can detect colorectal cancer with 88% accuracy, regardless of its stage or location. This non-invasive screening test offers a patient-friendly alternative to traditional colonoscopy.
Researchers found whole-body PET/CT scans accurate in diagnosing colorectal cancer stages, changing patient management in 9% of cases. This non-invasive method offers a single-stage approach, reducing burden on patients and clinicians compared to conventional imaging procedures.
A multicenter study found that medium-sized colon polyps (0.6-0.9 cm) are associated with a significant number of advanced adenomas and cancers. This raises questions about the effectiveness of observational screening methods, which do not remove polyps.
Researchers developed a vaccine that stimulates colorectal cancer patients' immune systems to fight cancerous cells, with 70% of patients producing TNF-alpha and GM-CSF in response. The vaccine works by generating infection-fighting white blood cells called T cells, which destroy cancer cells.
A new set of quality indicators has been created to evaluate the quality of care received by patients undergoing colorectal cancer surgery. The guidelines cover aspects of surgical care, including pre-operative evaluation and post-operative management, to provide a valuable tool for improving patient outcomes.
Researchers identified 142 candidate indicators of quality care for colorectal cancer surgery, including surgical credentials, preoperative evaluation, and postoperative management. The expert panel rated 92 indicators as valid, suggesting these can be used to measure care quality and create improvement programs.
Studies found that colorectal cancer screening rates are increasing among Veterans Affairs patients, while younger veterans with other illnesses may not benefit from screening and may even be harmed. Screening methods include fecal occult blood testing and colonoscopy.
A new study by McGill University researchers has found that a diet low in folate may increase the risk of developing colorectal cancer. The study demonstrates a clear link between low dietary folate and the initiation of colorectal cancer in animal models, with 1 in 4 mice on a folate-deficient diet developing at least one tumour.
A new study found that only 33.3% of patients with locally advanced colorectal cancer received the recommended extensive surgery, which reduces local recurrence and improves survival rates. Aspirin takers with a specific genetic variant showed lower risk of developing colorectal adenomas.
A study published in Radiology found that virtual colonoscopy is an accurate screening method for colorectal cancer. The procedure was shown to be safer, faster, less costly, more convenient, and just as effective as optical colonoscopy in detecting polyps and cancers.
Researchers discovered a new target for future colon cancer treatments, a molecule involved in 85% of colon cancer cases. CTBP's accumulation in tumor cells with APC mutations leads to low retinoic acid production, causing improper cell development.
Two studies developed clinical models, PREMM1,2 and MMRpro, to predict the presence of mutations in MLH1 and MSH2 genes associated with Lynch syndrome. The models accurately estimated genetic risk for colorectal cancer, providing a timely tool for identifying and counseling families at risk.
A new prediction model, MMRpro, assesses a person's probability of carrying a particular defect in mismatch repair genes, which predisposes families to colorectal cancer. The study found that MMRpro outperformed existing assessment tools in identifying mutation carriers and predicting colon cancer risk.
Researchers at the University of Texas Medical Branch at Galveston discovered that curcumin blocks the activity of gastrointestinal hormone neurotensin, implicated in colorectal cancer development. Curcumin reduces IL-8 production, accelerating tumor growth and metastasis.
A new biomarker predicting survival in colorectal carcinomas has been discovered, with thymidylate synthase levels in the nucleus and cytoplasm identified as critical markers. The ratio of nuclear to cytoplasmic TS levels also predicts decreased survival, revealing a new potential biomarker for patients with worse prognosis.
The APPROVe trial shows rofecoxib effective in reducing the recurrence of colorectal adenomas, a precursor to colon cancer. Patients taking rofecoxib had a lower recurrence rate (41% vs 55%) and reduced risk of advanced adenomas compared to those on placebo.
A recent study published in the New England Journal of Medicine found that celecoxib, a commonly used painkiller, significantly reduced the incidence of potentially pre-malignant colorectal polyps by 36% in patients taking a daily dose. The study involved over 1,550 participants and showed a greater effect on advanced adenomas.
A study of over 9,000 Danish residents found that a specific variation in the CHEK2 gene triples a woman's risk of developing breast cancer in her lifetime. Women with this mutation are three times as likely to develop breast cancer as those without it.
A study of low-income housing residents found that those who watched more TV took fewer steps and were less likely to meet the recommended daily step count. The research used pedometers to measure physical activity and was conducted by researchers from Dana-Farber Cancer Institute.
A randomized controlled trial found that low-income Chinese-speaking patients were six times more likely to be screened for colorectal cancer when a clinic-based health educator provided culturally and linguistically appropriate counseling, educational materials, and screening test instructions. The intervention increased fecal occult ...
A large population-based study found that long-term smokers who never used NSAIDs had the highest risk of colon cancer. Smokers using NSAIDs still faced a 30% higher risk than nonsmokers. The study suggests NSAIDs may not counteract smoking's adverse effects on colorectal-cancer risk.
Researchers have developed a new test to detect rare genetic mutations in families at risk of passing on hereditary cancers like FAP. The innovative test allows for precise detection of mutations, enabling couples to make informed decisions about their pregnancies.
The study demonstrated a statistically significant benefit of FOLFIRI in patients with metastatic colorectal cancer, improving progression-free survival and overall survival. Adding bevacizumab to FOLFIRI also showed improved outcomes, with a higher percentage of patients alive after one year.
Long-term cancer survivors experience ongoing concerns about cancer recurrence and treatment side effects, affecting their mental health. Research found that these worries are linked to depression and anxiety, with varying levels of concern across different types of cancer.
Researchers used small interfering RNAs to block the spread of human colorectal cancer cells in laboratory mice, achieving a major reduction in liver cancer growth. The treatment also showed potential for increased cancer cell killing when combined with standard chemotherapeutic agents.
A study analyzed data from over 35,975 individuals who underwent colonoscopy without detecting colorectal neoplasia. The results showed a significant decrease in colorectal cancer incidence at 6 months (31%) and persisted for more than 10 years. A negative colonoscopy was associated with a lower risk of developing CRC.
A series of articles ranks preventive services by their cost-effectiveness and population health benefits, highlighting influenza vaccines and colorectal cancer screening as top priorities. The studies show that these services can save thousands of years of life and prevent deaths, with significant potential for improving overall healt...
Researchers recommend pre-screening to avoid worst liver damage caused by chemotherapy drugs. The study found that irinotecan was associated with steatohepatitis and oxaliplatin with sinusoidal dilation, which can lead to liver disease and failure.
Panitumumab significantly improves progression-free survival and disease control in patients with mCRC, with a median duration of response of 17 weeks. The treatment was well-tolerated, with few major adverse reactions.
Researchers found that MMP-9 is highly expressed by colon cancer cells and is key to initiating metastasis. By blocking the enzyme, colorectal cancer cells cannot metastasize to other tissue, suggesting a new target for preventing metastasis in colon cancer.